Forebyggelse af herpes zoster med vaccination

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Forebyggelse af herpes zoster med vaccination. / Kofoed, Kristian; Rønholt, Finn; Gerstoft, Jan; Sand, Carsten.

In: Ugeskrift for Laeger, Vol. 173, No. 2, 10.01.2011, p. 110-4.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kofoed, K, Rønholt, F, Gerstoft, J & Sand, C 2011, 'Forebyggelse af herpes zoster med vaccination', Ugeskrift for Laeger, vol. 173, no. 2, pp. 110-4.

APA

Kofoed, K., Rønholt, F., Gerstoft, J., & Sand, C. (2011). Forebyggelse af herpes zoster med vaccination. Ugeskrift for Laeger, 173(2), 110-4.

Vancouver

Kofoed K, Rønholt F, Gerstoft J, Sand C. Forebyggelse af herpes zoster med vaccination. Ugeskrift for Laeger. 2011 Jan 10;173(2):110-4.

Author

Kofoed, Kristian ; Rønholt, Finn ; Gerstoft, Jan ; Sand, Carsten. / Forebyggelse af herpes zoster med vaccination. In: Ugeskrift for Laeger. 2011 ; Vol. 173, No. 2. pp. 110-4.

Bibtex

@article{63e49e0c637e49b9ab9881e3837c8420,
title = "Forebyggelse af herpes zoster med vaccination",
abstract = "Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.",
author = "Kristian Kofoed and Finn R{\o}nholt and Jan Gerstoft and Carsten Sand",
year = "2011",
month = jan,
day = "10",
language = "Dansk",
volume = "173",
pages = "110--4",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "2",

}

RIS

TY - JOUR

T1 - Forebyggelse af herpes zoster med vaccination

AU - Kofoed, Kristian

AU - Rønholt, Finn

AU - Gerstoft, Jan

AU - Sand, Carsten

PY - 2011/1/10

Y1 - 2011/1/10

N2 - Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.

AB - Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.

M3 - Tidsskriftartikel

VL - 173

SP - 110

EP - 114

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 2

ER -

ID: 40154850